1 Scope of the Report

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Opioid-Induced Constipation Consumption 2016-2026

2.1.2 Opioid-Induced Constipation Consumption CAGR by Region

2.2 Opioid-Induced Constipation Segment by Type

2.2.1 Methylnaltrexone Bromide

2.2.2 Lubiprostone

2.2.3 Naloxegol

2.2.4 Others

2.3 Opioid-Induced Constipation Sales by Type

2.3.1 Global Opioid-Induced Constipation Sales Market Share by Type (2016-2021)

2.3.2 Global Opioid-Induced Constipation Revenue and Market Share by Type (2016-2021)

2.3.3 Global Opioid-Induced Constipation Sale Price by Type (2016-2021)

2.4 Opioid-Induced Constipation Segment by Application

2.4.1 Hospital

2.4.2 Pharmacy

2.5 Opioid-Induced Constipation Sales by Application

2.5.1 Global Opioid-Induced Constipation Sale Market Share by Application (2016-2021)

2.5.2 Global Opioid-Induced Constipation Revenue and Market Share by Application (2016-2021)

2.5.3 Global Opioid-Induced Constipation Sale Price by Application (2016-2021)

3 Global Opioid-Induced Constipation by Company

3.1 Global Opioid-Induced Constipation Sales Market Share by Company

3.1.1 Global Opioid-Induced Constipation Sales by Company (2019-2021)

3.1.2 Global Opioid-Induced Constipation Sales Market Share by Company (2019-2021)

3.2 Global Opioid-Induced Constipation Revenue Market Share by Company

3.2.1 Global Opioid-Induced Constipation Revenue by Company (2019-2021)

3.2.2 Global Opioid-Induced Constipation Revenue Market Share by Company (2019-2021)

3.3 Global Opioid-Induced Constipation Sale Price by Company

3.4 Global Manufacturers Opioid-Induced Constipation Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Opioid-Induced Constipation Product Location Distribution

3.4.2 Players Opioid-Induced Constipation Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 Opioid-Induced Constipation by Region

4.1 Global Opioid-Induced Constipation by Region

4.1.1 Global Opioid-Induced Constipation Sales by Region

4.1.2 Global Opioid-Induced Constipation Revenue by Region

4.2 Americas Opioid-Induced Constipation Sales Growth

4.3 APAC Opioid-Induced Constipation Sales Growth

4.4 Europe Opioid-Induced Constipation Sales Growth

4.5 Middle East & Africa Opioid-Induced Constipation Sales Growth

5 Americas

5.1 Americas Opioid-Induced Constipation Sales by Country

5.1.1 Americas Opioid-Induced Constipation Sales by Country (2016-2021)

5.1.2 Americas Opioid-Induced Constipation Revenue by Country (2016-2021)

5.2 Americas Opioid-Induced Constipation Sales by Type

5.3 Americas Opioid-Induced Constipation Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Opioid-Induced Constipation Sales by Region

6.1.1 APAC Opioid-Induced Constipation Sales by Region (2016-2021)

6.1.2 APAC Opioid-Induced Constipation Revenue by Region (2016-2021)

6.2 APAC Opioid-Induced Constipation Sales by Type

6.3 APAC Opioid-Induced Constipation Sales by Application

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 Europe

7.1 Europe Opioid-Induced Constipation by Country

7.1.1 Europe Opioid-Induced Constipation Sales by Country (2016-2021)

7.1.2 Europe Opioid-Induced Constipation Revenue by Country (2016-2021)

7.2 Europe Opioid-Induced Constipation Sales by Type

7.3 Europe Opioid-Induced Constipation Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Opioid-Induced Constipation by Country

8.1.1 Middle East & Africa Opioid-Induced Constipation Sales by Country (2016-2021)

8.1.2 Middle East & Africa Opioid-Induced Constipation Revenue by Country (2016-2021)

8.2 Middle East & Africa Opioid-Induced Constipation Sales by Type

8.3 Middle East & Africa Opioid-Induced Constipation Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Country

9 Market Drivers, Challenges and Trends

9.1 Market Drivers and Impact

9.1.1 Growing Demand from Key Regions

9.1.2 Growing Demand from Key Applications and Potential Industries

9.2 Market Challenges and Impact

9.3 Market Trends

10 Marketing, Distributors and Customer

10.1 Sales Channel

10.1.1 Direct Channels

10.1.2 Indirect Channels

10.2 Opioid-Induced Constipation Distributors

10.3 Opioid-Induced Constipation Customer

11 Global Opioid-Induced Constipation Market Forecast

11.1 Global Opioid-Induced Constipation Forecast by Region

11.1.1 Global Opioid-Induced Constipation Forecast by Regions (2021-2026)

11.2.2 Global Opioid-Induced Constipation Revenue Forecast by Regions (2021-2026)

11.2 Americas Forecast by Country

11.3 APAC Forecast by Region

11.4 Europe Forecast by Country

11.5 Middle East & Africa Forecast by Country

11.6 Global Opioid-Induced Constipation Forecast by Type

11.7 Global Opioid-Induced Constipation Forecast by Application

12 Key Players Analysis

12.1 Takeda Pharmaceuticals

12.1.1 Takeda Pharmaceuticals Company Information

12.1.2 Takeda Pharmaceuticals Opioid-Induced Constipation Product Offered

12.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)

12.1.4 Takeda Pharmaceuticals Main Business Overview

12.1.5 Takeda Pharmaceuticals Latest Developments

12.2 Bayer

12.2.1 Bayer Company Information

12.2.2 Bayer Opioid-Induced Constipation Product Offered

12.2.3 Bayer Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)

12.2.4 Bayer Main Business Overview

12.2.5 Bayer Latest Developments

12.3 Sanofi

12.3.1 Sanofi Company Information

12.3.2 Sanofi Opioid-Induced Constipation Product Offered

12.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)

12.3.4 Sanofi Main Business Overview

12.3.5 Sanofi Latest Developments

12.4 Mallinckrodt

12.4.1 Mallinckrodt Company Information

12.4.2 Mallinckrodt Opioid-Induced Constipation Product Offered

12.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)

12.4.4 Mallinckrodt Main Business Overview

12.4.5 Mallinckrodt Latest Developments

12.5 Salix (Bausch Health)

12.5.1 Salix (Bausch Health) Company Information

12.5.2 Salix (Bausch Health) Opioid-Induced Constipation Product Offered

12.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)

12.5.4 Salix (Bausch Health) Main Business Overview

12.5.5 Salix (Bausch Health) Latest Developments

12.6 AstraZeneca

12.6.1 AstraZeneca Company Information

12.6.2 AstraZeneca Opioid-Induced Constipation Product Offered

12.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)

12.6.4 AstraZeneca Main Business Overview

12.6.5 AstraZeneca Latest Developments

12.7 Progenics Pharmaceuticals

12.7.1 Progenics Pharmaceuticals Company Information

12.7.2 Progenics Pharmaceuticals Opioid-Induced Constipation Product Offered

12.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)

12.7.4 Progenics Pharmaceuticals Main Business Overview

12.7.5 Progenics Pharmaceuticals Latest Developments

12.8 Purdue Pharm

12.8.1 Purdue Pharm Company Information

12.8.2 Purdue Pharm Opioid-Induced Constipation Product Offered

12.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)

12.8.4 Purdue Pharm Main Business Overview

12.8.5 Purdue Pharm Latest Developments

12.9 Nektar Therapeutics

12.9.1 Nektar Therapeutics Company Information

12.9.2 Nektar Therapeutics Opioid-Induced Constipation Product Offered

12.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)

12.9.4 Nektar Therapeutics Main Business Overview

12.9.5 Nektar Therapeutics Latest Developments

12.10 Daiichi Sankyo

12.10.1 Daiichi Sankyo Company Information

12.10.2 Daiichi Sankyo Opioid-Induced Constipation Product Offered

12.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)

12.10.4 Daiichi Sankyo Main Business Overview

12.10.5 Daiichi Sankyo Latest Developments

12.11 Prestige

12.11.1 Prestige Company Information

12.11.2 Prestige Opioid-Induced Constipation Product Offered

12.11.3 Prestige Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)

12.11.4 Prestige Main Business Overview

12.11.5 Prestige Latest Developments

12.12 GSK

12.12.1 GSK Company Information

12.12.2 GSK Opioid-Induced Constipation Product Offered

12.12.3 GSK Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)

12.12.4 GSK Main Business Overview

12.12.5 GSK Latest Developments

12.13 Shionogi

12.13.1 Shionogi Company Information

12.13.2 Shionogi Opioid-Induced Constipation Product Offered

12.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2019-2021)

12.13.4 Shionogi Main Business Overview

12.13.5 Shionogi Latest Developments

13 Research Findings and Conclusion

List of Tables

Table 1. Opioid-Induced Constipation Consumption CAGR by Region (2020-2026) & ($ Millions)

Table 2. Major Players of Methylnaltrexone Bromide

Table 3. Major Players of Lubiprostone

Table 4. Major Players of Naloxegol

Table 5. Major Players of Others

Table 6. Global Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)

Table 7. Global Opioid-Induced Constipation Sales Market Share by Type (2016-2021)

Table 8. Global Opioid-Induced Constipation Revenue by Type (2016-2021) & ($ million)

Table 9. Global Opioid-Induced Constipation Revenue Market Share by Type (2016-2021)

Table 10. Global Opioid-Induced Constipation Sale Price by Type (2016-2021)

Table 11. Global Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)

Table 12. Global Opioid-Induced Constipation Sales Market Share by Application (2016-2021)

Table 13. Global Opioid-Induced Constipation Value by Application (2016-2021)

Table 14. Global Opioid-Induced Constipation Revenue Market Share by Application (2016-2021)

Table 15. Global Opioid-Induced Constipation Sale Price by Application (2016-2021)

Table 16. Global Opioid-Induced Constipation Sales by Company (2019-2021) & (K Units)

Table 17. Global Opioid-Induced Constipation Sales Market Share by Company (2019-2021)

Table 18. Global Opioid-Induced Constipation Revenue by Company (2019-2021) ($ Millions)

Table 19. Global Opioid-Induced Constipation Revenue Market Share by Company (2019-2021)

Table 20. Global Opioid-Induced Constipation Sale Price by Company (2019-2021)

Table 21. Key Manufacturers Opioid-Induced Constipation Producing Area Distribution and Sales Area

Table 22. Players Opioid-Induced Constipation Products Offered

Table 23. Opioid-Induced Constipation Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)

Table 24. New Products and Potential Entrants

Table 25. Mergers & Acquisitions, Expansion

Table 26. Global Opioid-Induced Constipation Sales by Region (2016-2021) (K Units)

Table 27. Global Opioid-Induced Constipation Sales Market Share by Region (2016-2021)

Table 28. Global Opioid-Induced Constipation Revenue by Region (2016-2021) & ($ Millions)

Table 29. Global Opioid-Induced Constipation Revenue Market Share by Region (2016-2021)

Table 30. Americas Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)

Table 31. Americas Opioid-Induced Constipation Sales Market Share by Country (2016-2021)

Table 32. Americas Opioid-Induced Constipation Revenue by Country (2016-2021) & ($ Millions)

Table 33. Americas Opioid-Induced Constipation Revenue Market Share by Country (2016-2021)

Table 34. Americas Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)

Table 35. Americas Opioid-Induced Constipation Sales Market Share by Type (2016-2021)

Table 36. Americas Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)

Table 37. Americas Opioid-Induced Constipation Sales Market Share by Application (2016-2021)

Table 38. APAC Opioid-Induced Constipation Sales by Region (2016-2021) & (K Units)

Table 39. APAC Opioid-Induced Constipation Sales Market Share by Region (2016-2021)

Table 40. APAC Opioid-Induced Constipation Revenue by Region (2016-2021) & ($ Millions)

Table 41. APAC Opioid-Induced Constipation Revenue Market Share by Region (2016-2021)

Table 42. APAC Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)

Table 43. APAC Opioid-Induced Constipation Sales Market Share by Type (2016-2021)

Table 44. APAC Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)

Table 45. APAC Opioid-Induced Constipation Sales Market Share by Application (2016-2021)

Table 46. Europe Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)

Table 47. Europe Opioid-Induced Constipation Sales Market Share by Country (2016-2021)

Table 48. Europe Opioid-Induced Constipation Revenue by Country (2016-2021) & ($ Millions)

Table 49. Europe Opioid-Induced Constipation Revenue Market Share by Country (2016-2021)

Table 50. Europe Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)

Table 51. Europe Opioid-Induced Constipation Sales Market Share by Type (2016-2021)

Table 52. Europe Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)

Table 53. Europe Opioid-Induced Constipation Sales Market Share by Application (2016-2021)

Table 54. Middle East & Africa Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)

Table 55. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Country (2016-2021)

Table 56. Middle East & Africa Opioid-Induced Constipation Revenue by Country (2016-2021) & ($ Millions)

Table 57. Middle East & Africa Opioid-Induced Constipation Revenue Market Share by Country (2016-2021)

Table 58. Middle East & Africa Opioid-Induced Constipation Sales by Type (2016-2021) & (K Units)

Table 59. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Type (2016-2021)

Table 60. Middle East & Africa Opioid-Induced Constipation Sales by Application (2016-2021) & (K Units)

Table 61. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Application (2016-2021)

Table 62. Key and Potential Regions of Opioid-Induced Constipation

Table 63. Key Application and Potential Industries of Opioid-Induced Constipation

Table 64. Key Challenges of Opioid-Induced Constipation

Table 65. Key Trends of Opioid-Induced Constipation

Table 66. Opioid-Induced Constipation Distributors List

Table 67. Opioid-Induced Constipation Customer List

Table 68. Global Opioid-Induced Constipation Sales Forecast by Region (2021-2026) & (K Units)

Table 69. Global Opioid-Induced Constipation Consumption Market Forecast by Region

Table 70. Global Opioid-Induced Constipation Revenue Forecast by Region (2021-2026) & ($ millions)

Table 71. Global Opioid-Induced Constipation Revenue Market Share Forecast by Region (2021-2026)

Table 72. Americas Opioid-Induced Constipation Sales Forecast by Country (2021-2026) & (K Units)

Table 73. Americas Opioid-Induced Constipation Revenue Forecast by Country (2021-2026) & ($ millions)

Table 74. APAC Opioid-Induced Constipation Sales Forecast by Region (2021-2026) & (K Units)

Table 75. APAC Opioid-Induced Constipation Revenue Forecast by Region (2021-2026) & ($ millions)

Table 76. Europe Opioid-Induced Constipation Sales Forecast by Country (2021-2026) & (K Units)

Table 77. Europe Opioid-Induced Constipation Revenue Forecast by Country (2021-2026) & ($ millions)

Table 78. Middle East & Africa Opioid-Induced Constipation Sales Forecast by Country (2021-2026) & (K Units)

Table 79. Middle East & Africa Opioid-Induced Constipation Revenue Forecast by Country (2021-2026) & ($ millions)

Table 80. Global Opioid-Induced Constipation Sales Forecast by Type (2021-2026) & (K Units)

Table 81. Global Opioid-Induced Constipation Sales Market Share Forecast by Type (2021-2026)

Table 82. Global Opioid-Induced Constipation Revenue Forecast by Type (2021-2026) & ($ Millions)

Table 83. Global Opioid-Induced Constipation Revenue Market Share Forecast by Type (2021-2026)

Table 84. Global Opioid-Induced Constipation Sales Forecast by Application (2021-2026) & (K Units)

Table 85. Global Opioid-Induced Constipation Sales Market Share Forecast by Application (2021-2026)

Table 86. Global Opioid-Induced Constipation Revenue Forecast by Application (2021-2026) & ($ Millions)

Table 87. Global Opioid-Induced Constipation Revenue Market Share Forecast by Application (2021-2026)

Table 88. Takeda Pharmaceuticals Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 89. Takeda Pharmaceuticals Opioid-Induced Constipation Product Offered

Table 90. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)

Table 91. Takeda Pharmaceuticals Main Business

Table 92. Takeda Pharmaceuticals Latest Developments

Table 93. Bayer Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 94. Bayer Opioid-Induced Constipation Product Offered

Table 95. Bayer Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)

Table 96. Bayer Main Business

Table 97. Bayer Latest Developments

Table 98. Sanofi Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 99. Sanofi Opioid-Induced Constipation Product Offered

Table 100. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)

Table 101. Sanofi Main Business

Table 102. Sanofi Latest Developments

Table 103. Mallinckrodt Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 104. Mallinckrodt Opioid-Induced Constipation Product Offered

Table 105. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)

Table 106. Mallinckrodt Main Business

Table 107. Mallinckrodt Latest Developments

Table 108. Salix (Bausch Health) Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 109. Salix (Bausch Health) Opioid-Induced Constipation Product Offered

Table 110. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)

Table 111. Salix (Bausch Health) Main Business

Table 112. Salix (Bausch Health) Latest Developments

Table 113. AstraZeneca Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 114. AstraZeneca Opioid-Induced Constipation Product Offered

Table 115. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)

Table 116. AstraZeneca Main Business

Table 117. AstraZeneca Latest Developments

Table 118. Progenics Pharmaceuticals Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 119. Progenics Pharmaceuticals Opioid-Induced Constipation Product Offered

Table 120. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)

Table 121. Progenics Pharmaceuticals Main Business

Table 122. Progenics Pharmaceuticals Latest Developments

Table 123. Purdue Pharm Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 124. Purdue Pharm Opioid-Induced Constipation Product Offered

Table 125. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)

Table 126. Purdue Pharm Main Business

Table 127. Purdue Pharm Latest Developments

Table 128. Nektar Therapeutics Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 129. Nektar Therapeutics Opioid-Induced Constipation Product Offered

Table 130. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)

Table 131. Nektar Therapeutics Main Business

Table 132. Nektar Therapeutics Latest Developments

Table 133. Daiichi Sankyo Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 134. Daiichi Sankyo Opioid-Induced Constipation Product Offered

Table 135. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)

Table 136. Daiichi Sankyo Main Business

Table 137. Daiichi Sankyo Latest Developments

Table 138. Prestige Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 139. Prestige Opioid-Induced Constipation Product Offered

Table 140. Prestige Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)

Table 141. Prestige Main Business

Table 142. Prestige Latest Developments

Table 143. GSK Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 144. GSK Opioid-Induced Constipation Product Offered

Table 145. GSK Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)

Table 146. GSK Main Business

Table 147. GSK Latest Developments

Table 148. Shionogi Basic Information, Opioid-Induced Constipation Manufacturing Base, Sales Area and Its Competitors

Table 149. Shionogi Opioid-Induced Constipation Product Offered

Table 150. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)

Table 151. Shionogi Main Business

Table 152. Shionogi Latest Developments

List of Figures

Figure 1. Picture of Opioid-Induced Constipation

Figure 2. Opioid-Induced Constipation Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Opioid-Induced Constipation Sales Growth Rate 2016-2026 (K Units)

Figure 7. Global Opioid-Induced Constipation Revenue Growth Rate 2016-2026 ($ Millions)

Figure 8. Opioid-Induced Constipation Sales by Region (2021 & 2026) & ($ millions)

Figure 9. Product Picture of Methylnaltrexone Bromide

Figure 10. Product Picture of Lubiprostone

Figure 11. Product Picture of Naloxegol

Figure 12. Product Picture of Others

Figure 13. Global Opioid-Induced Constipation Sales Market Share by Type in 2020

Figure 14. Global Opioid-Induced Constipation Revenue Market Share by Type (2016-2021)

Figure 15. Opioid-Induced Constipation Consumed in Hospital

Figure 16. Global Opioid-Induced Constipation Market: Hospital (2016-2021) & (K Units)

Figure 17. Opioid-Induced Constipation Consumed in Pharmacy

Figure 18. Global Opioid-Induced Constipation Market: Pharmacy (2016-2021) & (K Units)

Figure 19. Global Opioid-Induced Constipation Sales Market Share by Application (2016-2021)

Figure 20. Global Opioid-Induced Constipation Revenue Market Share by Application in 2020

Figure 21. Opioid-Induced Constipation Revenue Market by Company in 2020 ($ Million)

Figure 22. Global Opioid-Induced Constipation Revenue Market Share by Company in 2020

Figure 23. Global Opioid-Induced Constipation Sales Market Share by Regions (2016-2021)

Figure 24. Global Opioid-Induced Constipation Revenue Market Share by Region in 2020

Figure 25. Americas Opioid-Induced Constipation Sales 2016-2021 (K Units)

Figure 26. Americas Opioid-Induced Constipation Revenue 2016-2021 ($ Millions)

Figure 27. APAC Opioid-Induced Constipation Sales 2016-2021 (K Units)

Figure 28. APAC Opioid-Induced Constipation Revenue 2016-2021 ($ Millions)

Figure 29. Europe Opioid-Induced Constipation Sales 2016-2021 (K Units)

Figure 30. Europe Opioid-Induced Constipation Revenue 2016-2021 ($ Millions)

Figure 31. Middle East & Africa Opioid-Induced Constipation Sales 2016-2021 (K Units)

Figure 32. Middle East & Africa Opioid-Induced Constipation Revenue 2016-2021 ($ Millions)

Figure 33. Americas Opioid-Induced Constipation Sales Market Share by Country in 2020

Figure 34. Americas Opioid-Induced Constipation Revenue Market Share by Country in 2020

Figure 35. Americas Opioid-Induced Constipation Sales Market Share by Type in 2020

Figure 36. Americas Opioid-Induced Constipation Sales Market Share by Application in 2020

Figure 37. United States Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 38. Canada Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 39. Mexico Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 40. Brazil Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 41. APAC Opioid-Induced Constipation Sales Market Share by Region in 2020

Figure 42. APAC Opioid-Induced Constipation Revenue Market Share by Regions in 2020

Figure 43. APAC Opioid-Induced Constipation Sales Market Share by Type in 2020

Figure 44. APAC Opioid-Induced Constipation Sales Market Share by Application in 2020

Figure 45. China Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 46. Japan Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 47. Korea Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 48. Southeast Asia Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 49. India Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 50. Australia Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 51. Europe Opioid-Induced Constipation Sales Market Share by Country in 2020

Figure 52. Europe Opioid-Induced Constipation Revenue Market Share by Country in 2020

Figure 53. Europe Opioid-Induced Constipation Sales Market Share by Type in 2020

Figure 54. Europe Opioid-Induced Constipation Sales Market Share by Application in 2020

Figure 55. Germany Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 56. France Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 57. UK Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 58. Italy Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 59. Russia Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 60. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Country in 2020

Figure 61. Middle East & Africa Opioid-Induced Constipation Revenue Market Share by Country in 2020

Figure 62. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Type in 2020

Figure 63. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Application in 2020

Figure 64. Egypt Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 65. South Africa Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 66. Israel Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 67. Turkey Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 68. GCC Country Opioid-Induced Constipation Revenue Growth 2016-2021 ($ Millions)

Figure 69. Channels of Distribution

Figure 70. Distributors Profiles